December 2014

New Product - Pomalyst

Pomalyst (pomalidomide) is an immunomodulating agent which has direct antimyeloma tumouricidal activity, immunomodulatory activities and inhibits stromal cell support for multiple myeloma tumour cell growth. Specifically, pomalidomide inhibits proliferation and induces apoptosis of haematopoietic tumour cells. Pomalidomide, in combination with dexamethasone, is indicated for the treatment of patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy. Pomalidomide is contraindicated in pregnancy and in females of childbearing potential and male patients unless all of the conditions of the i-access Program have been met. Pomalyst is available as 1 mg, 2 mg, 3 mg and 4 mg capsules in packs of 21’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629